Функциональные ответы альвеолярных макрофагов, сурфактантный белок D и заболевания легких


https://doi.org/10.18093/0869-0189-2011-0-3-101-107

Полный текст:


Аннотация

Функциональные ответы альвеолярных макрофагов, сурфактантный белок D и заболевания легких.


Об авторах

И. Ю. Малышев
ГОУ ВПО "Московский государственный медико-стоматологический университет Федерального агентства по здравоохранению и социальному развитию"; НИИ общей патологии и патофизиологии РАМН
Россия

д. м. н., проф., зав. лабораторией клеточных биотехнологий, зав. лабораторией стресса и адаптацией

127473, Москва, ул. Делегатская, 20 / 1

25315, Москва, ул. Балтийская, 8. Тел.: +7-985-766-24-40.



С. В. Лямина
ГОУ ВПО "Московский государственный медико-стоматологический университет Федерального агентства по здравоохранению и социальному развитию"
Россия

к. м. н., старший научный сотрудник лаборатории клеточных биотехнологий

127473, Москва, ул. Делегатская, 20 / 1. Тел.: +7-915-018-50-06.



Ш. Л. Шимшелашвили
ГОУ ВПО "Московский государственный медико-стоматологический университет Федерального агентства по здравоохранению и социальному развитию"
Россия

к. м. н., ассистент кафедры госпитальной терапевтической стоматологии, пародонтологии и гериатрической стоматологии 

127473, Москва, ул. Делегатская, 20 / 1. Тел.: +7-985-766-24-40.



Е. Н. Вассерман
Пенсильванский университет
Соединённые Штаты Америки

к. м. н., старший научный сотрудник Школы медицины, отделения легочной и интенсивной терапии 

Vernon and Shirley Hill Pavilion, # H410C 380 S. University Ave. Philadelphia, PA 19104-4539. Тел.: +7-985-766-24-40.



Список литературы

1. Чучалин А.Г. (ред.). Стандарты по диагностике и лечению больных хронической обструктивной болезнью легких (ATS / ERS, пересмотр 2004 г.). Пер. с англ. М.: Атмосфера; 2005.

2. Хаитов Р.М. Иммунология: Учебник. М.: ГЭОТАР-Медиа; 2006.

3. Janeway C.A., Travers P., Walport M., Shlomchik M. Immunobiology. The immune system in health and disease: New York: Garland Science Publishing, 2005.

4. Mantovani A., Sica A., Sozzani S. et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25: 677–686.

5. Mantovani A. Macrophage diversity and polarization: in vivo veritas. Blood 2006; 108 (2): 408–409.

6. Mantovani A., Sica A., Locatti A. New vistas on macrophage differentiation and activation. Eur. J. Immunol. 2006; 37 (1): 14–16.

7. Boehm U., Klamp T., Groot M., Howard J.C. Cellular responses to interferon-gamma. Ann. Rev. Immunol. 1997; 15: 749–795.

8. Sharma M. Chemokines and their receptors: orchestrating a fine balance between health and disease. Crit. Rev. Biotechnol. 2010; 30: 1–22.

9. Trost M., English L., Limieux S. et al. The phagosomal proteome in interferon-?-activated macrophages. Immunity 2009; 30 (1): 143–154.

10. Nelson S. Novel nonantibiotic therapies for pneumonia. Cytokines and host defence. Chest 2001; 119 (2): 419S–425S.

11. Martinez F.O., Gordon S., Locati A., Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: New molecules and patterns of gene expression. J. Immunol. 2006; 177: 7303–7311.

12. Kaplan A.P. Chemokines, chemokine receptors and allergy. Int. Arch. Allergy Immunol. 2001; 124 (4): 423–431.

13. Falcone F.H., Haas H., Gibbs B.F. The human basophil: a new appreciation of its role in immune responses. Blood 2000; 96 (13): 4028–4038.

14. D'Andrea A., Aste5Amezaga M., Valiante N.M. et al. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor / IL-12 synthesis in accessory cells. J. Exp. Med. 1993; 178 (3): 1041–1048.

15. Hu S., Sheng W.S., Peterson P.K., Chao C.C. Differential regulation by cytokines of production of nitric oxide by human astrocytes. Glia 1995; 15: 491–494.

16. Gordon S. The macrophage: Past, present and future. Eur. J. Immunol. 2007; 37: S9.

17. Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front. Biosci. 2008; 1 (13): 453–461.

18. Sieling P.A., Abrams J.S., Yamamura M. et al. Immunosuppressive roles for IL-10 and IL-4 in human infection. In vitro modulation of T cell responses in leprosy. J. Immunol. 1993; 150 (12): 5501–5510.

19. Oosterhout A.J.M., Motta A.C. Th1 / Th2 paradigm: not seeing the forest for the trees? Eur. Respir. J. 2005; 25: 591–593.

20. Mantovani A., Sozzani S., Locati M. et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002; 23 (11): 549–555.

21. Fritz J., Murphy B.S., Sundareshan V. et al. M1 and M2 Macrophage activation. Azithromycin alters macrophage phenotype. J. Antimicrob. Chemother. 2008; 61 (3): 554–560.

22. Atochina E.N., Beck J.M., Scanlon S.T. et al. Pneumocystis carinii pneumonia alters expression and distribution of lung collectins SP-A and SP-D. J. Lab. Clin. Med. 2001; 137: 429–39.

23. Atochina E.N., Beers M.F., Hawgood S. et al. Surfactant protein-D, a mediator of innate lung immunity, alters the products of nitric oxide metabolism. Am. J. Respir. Cell Mol. Biol. 2004; 30: 271–279.

24. Cheng G., Ueda T., Numao T. et al. Increased levels of surfactant protein A and D in bronchoalveolar lavage fluids in patients with bronchial asthma. Eur. Respir. J. 2000; 16: 831–835.

25. Cheng I.W., Ware L.B., Greene K.E. et al. Prognostic value of surfactant proteins A and D in patients with acute lung injury. Crit. Care Med. 2003; 31: 20–27.

26. Eisner M.D., Parsons P., Matthay M.A. et al. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax 2003; 58: 983–988.

27. Fujita M., Shannon J.M., Ouchi H. et al. Serum surfactant protein D is increased in acute and chronic inflammation in mice. Cytokine 2005; 31: 25–33.

28. Kuan S., Rust K., Crouch E. Interactions of surfactant protein D with bacterial lipopolysaccharides. J. Clin. Invest. 1992; 90: 97–106.

29. Wright J.R. Immunomodulatory functions of surfactant. Physiol. Rev. 1997; 77: 931–962.

30. Crouch E.C. Structure, biologic properties and expression of surfactant protein D. Biochim. Biophys. Acta 1998; 1408: 278–289.

31. Sorensen G.L., Husby S., Holmskov U. Surfactant protein A and surfactant protein D variation in pulmonary disease. Immunobiology 2007; 212 (4–5): 381–416.

32. Sin D.D., Pahlavan P.S., Man P.S.P. Surfactant protein D: A lung specific biomarker in COPD?: Potential biological roles of SP-D in COPD. Ther. Adv. Respir Dis. 2008; 2 (2): 65–74.

33. Fisher J.H., Larson J., Cool C., Dow S.W. Lymphocyte activation in the lungs of SP-D null mice. Am. J. Respir. Cell. Mol. Biol. 2002; 27: 24–33.

34. Botas C.F., Poulain J., Akiyama J. et al. Altered surfactant homeostasis and alveolar type II cell morphology in mice lacking surfactant protein D. Proc. Natl. Acad. Sci. USA 1998; 95:11869–11874.

35. Wert S.E., Yoshida M., LeVine A.M. et al. Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice. Proc. Natl. Acad. Sci. USA 1997; 97: 5972–5977.

36. Korfhagen T.R., Sheftelyevich V., Burhans M.S. et al. Surfactant protein-D regulates surfactant phospholipid homeostasis in vivo. J. Biol. Chem. 1998; 273: 28438–28443.

37. Yoshida M., Korfhagen Th.R., Whitsett J.A. Surfactant protein D regulates NF-κB and matrix metalloproteinase production in alveolar macrophages via oxidant-sensitive pathways. J. Immunol. 2001; 166: 7514–7519.

38. LeVine A.M., Whitsett J.A., Gwozdz J.A. et al. Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung. J. Immunol. 2000; 165: 3934–3940.

39. Gardai S.J., Xiao Y.5Q., Dickinson M. et al. By binding SIRP-alpha or calreticulin / CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell 2003; 115: 13–23.

40. Atochina5Vasserman E.N., Kadire H., Tomer Y. et al. Selective inhibition of iNOS activity in vivo reverses inflammatory abnormalities in SP-D deficient mice. J. Immunol. 2007; 179 (12): 8090–8097.

41. Atochina5Vasserman E.N., Abramova E.V., Tomer Y. et al. SP-D-Dependent regulation of NO metabolism in lipopolysaccharide-stimulated peritoneal macrophages. Bull. Exp. Biol. Med. 2009; 147 (4): 415–420.

42. Sano H., Kuroki Y. The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity. Mol. Immunol. 2005; 42 (3): 279–287.

43. Guo C.J., Atochina5Vasserman E.N., Abramova H. et al. S-Nitrosylation of surfactant protein-D controls inflammatory function. PLoS Biol. 2008; 6 (11): e266.

44. Zhang L., Ikegami M., Crouch E.C. et al. Activity of pulmonary surfactant protein-D (SP-D) in vivo is dependent on oligomeric structure. J. Biol. Chem. 2001; 276 (22): 19214–19219.

45. Guo C.J., Rashman C.S., Wolf B.A., Gow A.J. S-Nitrosylation of surfactant protein-D provides a molecular switch from anti- to pro-inflammatory function. Nitric Oxide 2006; 14 (4): 6.

46. McCormack F.X., Whitsett J.A. The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J. Clin. Invest 2002; 109 (6): 707–712.

47. Bartlett J.G., Breiman R.F., Mandell L.A. et al. Communityacquired pneumonia in adults-guidelines for management. Clin. Infect. Dis. 1998; 26: 811–838.

48. Bufler P., Schikor D., Schmidt B., Griese M. Cytokine stimulation by Pseudomonas aeruginosa strain variation and modulation by pulmonary surfactant. Exp. Lung Res. 2004; 30 (3): 163–179.

49. Lofdahl M., Wahlstorm J., Skold C.M. Different inflammatory cell pattern and macrophage phenotype in chronic obstructive pulmonary disease patients, smokers and non-smokers. Clin. Exp. Immunol. 2006; 145 (3): 428–437.

50. Pons A.R., Noguera A., Blanquer D. et al. Phenotypic characterization of alveolar macrophages and peripheral blood monocytes in COPD. Eur. Respir. J. 2005; 25 (4): 647–652.

51. Shaykhiev R., Krause A., Salit J. et al. Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. J. Immunol. 2009; 183: 2867–2883.

52. Лещенко И.В. Глобальная инициатива по хронической обструктивной болезни легких: новые направления в лечении. Урал. мед. Журн. 2006; 8 (36).

53. Sethi S., Maloney J., Grove L. et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Res. Med. COPD Update 2006; 1 (4): 144–145.

54. Доклад экспертов ВОЗ; 2005.

55. Woodruff P.G., Modrek B., Choy D.F. et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am. J. Respir. Crit. Care Med. 2009; 180 (5): 388–395.

56. Шмелев Е.И. Дифференциальная диагностика интерстициальных заболеваний легких. Consilium Medicum 2003; 5 (4): 176–181.

57. Kunitake R., Kuwano K., Yoshida K. et al. KL-6, surfactant protein A and D in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Respiration 2001; 68: 488–495.

58. Kucejko W., Chyczewska E., Naumnik W., Ossolinska M. Concentration of surfactant protein D, Clara cell protein CC-16 and IL-10 in bronchoalveolar lavage (BAL) in patients with sarcoidosis, hypersensivity pneumonitis and idiopathic pulmonary fibrosis. Folia Histochem. Cytobiol. 2009; 47 (2): 225–230.

59. Zissel G., Prasse A., Muller5Quernheim J. Sarcoidosisimmunopathogenetic concepts. J. Semin. Respir. Crit. Care Med. 2007; 28 (1): 3–14.

60. Prasse A., Georges C.G., Biller H. et al. Тh1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells. Clin. Exp. Immunol. 2000; 122 (2): 241–248.


Дополнительные файлы

Для цитирования: Малышев И.Ю., Лямина С.В., Шимшелашвили Ш.Л., Вассерман Е.Н. Функциональные ответы альвеолярных макрофагов, сурфактантный белок D и заболевания легких.  Пульмонология. 2011;(3):101-107. https://doi.org/10.18093/0869-0189-2011-0-3-101-107

For citation: Malyshev I.Y., Lyamina S.V., Shimshelashvili S.L., Vasserman E.N. Functions of alveolar macrophages and surfactant protein D in lung disease. Russian Pulmonology. 2011;(3):101-107. (In Russ.) https://doi.org/10.18093/0869-0189-2011-0-3-101-107

Просмотров: 197

Обратные ссылки

  • Обратные ссылки не определены.


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)